

# Regence

## Surgical Treatments for Glaucoma

Published: 01/01/2026

Next Review: 05/2026

Last Review: 07/2025

### IMPORTANT REMINDER

*The Medicare Advantage Medical Policy manual is not intended to override the member Evidence of Coverage (EOC), which defines the insured's benefits, nor is it intended to dictate how providers are to practice medicine. Physicians and other health care providers are expected to exercise their medical judgment in providing the most appropriate care for the individual member, including care that may be both medically reasonable and necessary.*

*The Medicare Advantage medical policies are designed to provide guidance regarding the decision-making process for the coverage or non-coverage of services or procedures in accordance with the member EOC and Centers of Medicare and Medicaid Services (CMS) policies and manuals, along with general CMS rules and regulations. In the event of a conflict, applicable CMS policy or EOC language will take precedence over the Medicare Advantage Medical Policy. In the absence of a specific CMS coverage determination for a requested service, item or procedure, the health plan may apply CMS regulations, as well as their Medical Policy Manual or other applicable utilization management vendor criteria developed with an objective, evidence-based process using scientific evidence, current generally accepted standards of medical practice, and authoritative clinical practice guidelines.*

*Some services or items may appear to be medically indicated for an individual but they may also be a direct exclusion of Medicare or the member's benefit plan. Medicare and member EOCs exclude from coverage, among other things, services or procedures considered to be investigational (experimental) or cosmetic, as well as services or items considered not medically reasonable and necessary under Title XVIII of the Social Security Act, §1862(a)(1)(A). In some cases, providers may bill members for these non-covered services or procedures. Providers are encouraged to inform members in advance when they may be financially responsible for the cost of non-covered or excluded services. Members, their appointed representative, or a treating provider can request coverage of a service or item by submitting a pre-service organization determination prior to services being rendered.*

### DESCRIPTION

Glaucoma surgery is intended to reduce intraocular pressure (IOP) when the target IOP cannot be reached using medications. Various minimally invasive techniques, including stents, shunts, laser trabeculostomy and femtosecond laser trabeculotomy have been proposed to improve fluid drainage from the eye to treat this disorder.

### MEDICARE ADVANTAGE POLICY CRITERIA

Notes: This policy does not address other procedures treatment glaucoma (e.g., laser trabeculoplasty, trabeculectomy).

*New and emerging medical technologies reported with Category III CPT Codes are created to track new, unproven therapies, devices, and tests. There are a number of reasons a service may be non-covered, including but not limited to, national coverage*

*determination (NCD) guidance, lack of FDA approval, or the service is not considered “medically reasonable or necessary” under Title XVIII of the Social Security Act, §1862(a)(1)(A).*

Procedure Name:	Code(s)	Criteria
<b>Micro-Invasive Glaucoma Surgery (MIGS)</b>	66989 66991	<p style="text-align: center;"><b>National Coverage Determinations (NCD)</b></p> <p>None</p> <p style="text-align: center;"><b>Noridian Healthcare Solutions (Noridian) Local Coverage Determinations (LCDs) and Articles</b></p> <p>Micro-invasive glaucoma surgery (MIGS) (L38299) (Companion article is A57863, which can be accessed directly from the LCD.</p> <p>Links to prior versions can be found at the bottom of the LCD.</p>
<b>Other Glaucoma Treatments</b>	See coding section	<p style="text-align: center;"><b>National Coverage Determinations (NCD)</b></p> <p>None</p> <p style="text-align: center;"><b>Noridian Healthcare Solutions (Noridian) Local Coverage Determinations (LCDs) and Articles</b></p> <p>None</p> <p style="text-align: center;"><b>Medical Policy Manual</b></p> <p><i>Medicare coverage guidance is not available for</i></p> <ul style="list-style-type: none"> <li>• <i>Laser trabeculotomy and trabeculectomy (0621T and 0622T), including optical coherence tomography (OCT) guidance (0730T)</i></li> <li>• <i>Travoprost drug eluting implants such as the iDose®TR (0660T, 0661T, J7355)</i></li> <li>• <i>Minimally invasive micro sclerostomy or trabeculectomy (1012T)</i></li> </ul> <p><i>Therefore, the health plan’s medical policy is applicable.</i></p> <p>Surgical Treatments for Glaucoma, Surgery, <a href="#">Policy No. 227</a> (see “NOTE” below)</p>

Procedure Name:	Code(s)	Criteria
		For Medicare Coverage Determinations and Articles, see the <a href="#">Medicare Coverage Database</a>
<p><b>NOTE:</b> If a procedure or device lacks scientific evidence regarding safety and efficacy because it is investigational or experimental, the service is noncovered as not reasonable and necessary to treat illness or injury. (<a href="#">Medicare IOM Pub. No. 100-04, Ch. 23, §30 A</a>). According to Title XVIII of the Social Security Act, §1862(a)(1)(A), only medically reasonable and necessary services are covered by Medicare. In the absence of a NCD, LCD, or other coverage guideline, CMS guidelines allow a Medicare Advantage Organization (MAO) to make coverage determinations, applying an objective, evidence-based process, based on authoritative evidence. (<a href="#">Medicare IOM Pub. No. 100-16, Ch. 4, §90.5</a>). The Medicare Advantage Medical Policy – Medicine Policy No. M-149 - provides further details regarding the plan’s evidence-assessment process (see Cross References).</p>		

## POLICY GUIDELINES

### REGULATORY STATUS

Regulatory status of ab interno aqueous shunts and microstents are summarized in Table 1.

In 2016, the XEN® Glaucoma Treatment System (Allergan), which consists of the XEN45 Gel Stent preloaded into the XEN Injector, was cleared for marketing by the FDA through the 510(k) process as an ab interno aqueous stent for management of refractory glaucoma. The approval was for patients with refractory glaucoma who failed previous surgical treatment or for patients with primary open-angle glaucoma unresponsive to maximum tolerated medical therapy. The FDA determined that this device was substantially equivalent to existing devices, specifically the Ahmed™ Glaucoma Valve and the EX-PRESS® Glaucoma Filtration Device.

In 2018, the first microstent, the iStent® Trabecular Micro-Bypass Stent preloaded into the iStent inject device (Glaukos) was approved by the FDA through the 515(d) process for use in conjunction with cataract surgery for the reduction of IOP in adults with mild-to-moderate OAG currently treated with ocular hypotensive medication.

In August 2018, Alcon announced an immediate voluntary recall of the CyPass microstent, which had been approved by the FDA in 2016 for use in conjunction with cataract surgery in adults with mild-to-moderate OAG. The recall was based on five-year postsurgery data from the COMPASS-XT long-term safety study. Results showed a statistically significant increase in endothelial cell loss among patients receiving the CyPass microstent compared with patients receiving cataract surgery alone.

**Table 1. Regulatory Status of Stents**

Device	Manufacturer	Type	FDA Status	Date
XEN® Gel Stent; XEN injector	AqueSys/Allergan	Aqueous glaucoma stent, ab interno	510(k)	2016

Device	Manufacturer	Type	FDA Status	Date
iStent®; iStent inject®	Glaukos	Microstent, ab interno	515(d) in conjunction with cataract surgery	2018
CyPass®	Alcon	Suprachoroidal stent, ab interno	Company voluntarily recalled	2018
Hydrus™	Ivantis	Microstent, ab interno	PMA approval	2018
iStent Infinite®	Glaukos	Microstent, ab interno	510k	2022

There are currently no excimer laser trabeculostomy/trabeculotomy (ELT), femtosecond laser trabeculotomy, or minimally invasive micro sclerostomy (MIMS) systems that are approved by the U.S Food and Drug Administration (FDA). The ExTra ELT laser platform and MIMS system are available in Europe.

The iDose®TR (Glaukos) was granted a New Drug Application (NDA) approval from the FDA in December 2023 (NDA# 218010). The iDose TR is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). The iDose®TR contains 75 mcg of travoprost pre-loaded in a single-dose inserter which is administered intracamerally through a small, clear corneal incision and is anchored into the sclera at the iridocorneal angle. The iDose®TR should not be readministered to an eye that received a prior iDose®TR. The iDose®TR (travoprost intracameral implant) is contraindicated in patients with

- active or suspected ocular or periocular infections.
- corneal Endothelial Dystrophy (e.g., Fuch’s Dystrophy, corneal guttatae).
- prior corneal transplantation, or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]).
- with hypersensitivity to travoprost or to any other components of the product.

The fact a new service or procedure has been issued a CPT/HCPCS code or is FDA approved for a specific indication does not, in itself, make the procedure medically reasonable and necessary. The FDA determines safety and effectiveness of a device or drug but does not establish medical necessity. While Medicare may adopt FDA determinations regarding safety and effectiveness, Medicare or Medicare contractors evaluate whether or not the drug or device is reasonable and necessary for the Medicare population under §1862(a)(1)(A)

## CROSS REFERENCES

1. [Investigational \(Experimental\) Services, New and Emerging Medical Technologies and Procedures, and Other Non-Covered Services](#), Medicine, Policy No. M-149

## REFERENCES

None

## CODING

**NOTE:** According to CPT guidelines, "If a category III code is available, this code must be reported instead of a Category I unlisted code." If a different CPT code (including an unlisted code, such as 64999) is used instead of one of the applicable Category III codes, the service is still noncovered per the Medicare reference noted in the "Medicare Advantage Policy Criteria" section of the policy.

<b>Codes</b>	<b>Number</b>	<b>Description</b>
<b>CPT</b>	0449T	Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; initial device
	0450T	Each additional device (List separately in addition to code for primary procedure)
	0474T	Insertion of anterior segment aqueous drainage device, with creation of intraocular reservoir, internal approach, into the supraciliary space
	0621T	Trabeculostomy ab interno by laser; (e.g., ExTra ELT)
	0622T	Trabeculostomy ab interno by laser; with use of ophthalmic endoscope
	0660T	Implantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach
	0661T	Removal and reimplantation of anterior segment intraocular nonbiodegradable drug eluting implant
	0730T	Trabeculotomy by laser, including optical coherence tomography (OCT) guidance
	1012T	Motorized ab interno trephination of sclera (sclerostomy), or trabecular meshwork (trabeculostomy), 1 or more, including injection of antifibrotic agents, when performed
	66989	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage; with insertion of intraocular (eg, trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more
	66991	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); with insertion of intraocular (eg, trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more
<b>HCPCS</b>	J7355	Injection, travoprost, intracameral implant, 1 mcg